Anatomical Therapeutic Chemical • L01EX04 • vandetanib

A Alimentary tract and metabolism

B Blood and blood forming organs

C Cardiovascular system

D Dermatologicals

G Genito urinary system and sex hormones

H Systemic hormonal preparations, excluding sex hormones and insulins

J Antiinfectives for systemic use

L Antineoplastic and immunomodulating agents

L01 Antineoplastic agents

L01A Alkylating agents

L01B Antimetabolites

L01C Plant alkaloids and other natural products

L01D Cytotoxic antibiotics and related substances

L01E Protein kinase inhibitors

L01EA BCR-ABL tyrosine kinase inhibitors

L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

L01EC B-raf serine-threonine kinase (BRAF) inhibitors

L01ED Anaplastic lymphoma kinase (ALK) inhibitors

L01EE Mitogen-activated protein kinase (MEK) inhibitors

L01EF Cyclin-dependent kinase (CDK) inhibitors

L01EG Mammalian target of rapamycin (MTOR) kinase inhibitors

L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors

L01EJ Janus-associated kinase (JAK) inhibitors

L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors

L01EL Bruton's tyrosine kinase (BTK) inhibitors

L01EM Phosphatidylinositol-3-kinase (PI3K) inhibitors

L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors

L01EP Cellular-mesenchymal-epithelial transition factor (c-met) kinase inhibitors

L01EX Other protein kinase inhibitors

L01EX01 sunitinib Indicated for: gastrointestinal stromal tumors

L01EX02 sorafenib Indicated for: cancer

L01EX03 pazopanib Indicated for: cancer

L01EX04 vandetanib Indicated for: cancer

L01EX05 regorafenib Indicated for: gastrointestinal stromal tumors

L01EX07 cabozantinib Indicated for: renal cell carcinoma; hepatocellular carcinoma; thyroid cancer

L01EX08 lenvatinib Indicated for: cancer

L01EX09 nintedanib Indicated for: cancer

L01EX10 midostaurin Indicated for: acute myeloid leukemia; systemic mastocytosis

L01EX11 quizartinib Indicated for: hematologic malignancies

L01EX12 larotrectinib Indicated for: cancer

L01EX13 gilteritinib Indicated for: cancer

L01EX14 entrectinib Indicated for: cancer

L01EX16 erdafitinib Indicated for: cancer

L01EX17 capmatinib Indicated for: non-small cell lung cancer

L01EX18 avapritinib Indicated for: gastrointestinal stromal tumors; systemic mastocytosis

L01EX19 ripretinib Indicated for: gastrointestinal stromal tumors

L01EX20 pemigatinib Indicated for: cancer

L01EX21 tepotinib Indicated for: non-small cell lung cancer

L01EX22 selpercatinib Indicated for: thyroid cancer; lung cancer

L01EX23 pralsetinib Indicated for: lung cancer; thyroid cancer

L01EX27 capivasertib Indicated for: breast cancer

L01F Monoclonal antibodies and antibody drug conjugates

L01X Other antineoplastic agents

L02 Endocrine therapy

L03 Immunostimulants

L04 Immunosuppressants

M Musculo-skeletal system

N Nervous system

P Antiparasitic products, insecticides and repellents

R Respiratory system

S Sensory organs

V Various